Steven Eschrich
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (24)
Background: Epigenetic changes associated with human papillomavirus (HPV)–driven tumors have been described; however, HPV type–specific alterations are less well understood. We sought to compare HPV16-specific methylation changes with those in virus-unassociated head and neck squamous cell carcinomas (HNSCC). Methods: Within The Cancer Genome Atlas, 59 HPV16 + HNSCC, 238 nonviral HNSCC (no detectable HPV or other viruses), and 50 normal head and neck tissues were evaluated. Significant differentially methylated regions (DMR) were selected, and key associated genes were identified. Partial least squares models were generated to predict HPV16 status in additional independent samples. Results: HPV infection in HNSCC is associated with type-specific methylomic profiles. Multiple significant DMRs were identified between HPV16 + , nonviral, and normal samples. The most significant differentially methylated genes, SYCP2, MSX2, HLTF, PITX2 , and GRAMD4 , demonstrated HPV16-associated methylation patterns with corresponding alterations in gene expression. Phylogenetically related HPV types (alpha-9 species; HPV31, HPV33, and HPV35) demonstrated a similar methylation profile to that of HPV16 but differed from those seen in other types, such as HPV18 and 45 (alpha-7). Conclusions: HNSCC linked to HPV16 and types from the same alpha species are associated with a distinct methylation profile. This HPV16-associated methylation pattern is also detected in cervical cancer and testicular germ cell tumors. We present insights into both shared and unique methylation alterations associated with HPV16 + tumors and may have implications for understanding the clinical behavior of HPV-associated HNSCC. Impact: HPV type–specific methylomic changes may contribute to understanding biologic mechanisms underlying differences in clinical behavior among different HPV + and HPV − HNSCC.
Year:
2025
TNBC is most common in the NHB cohort. A, Stacked bar chart showing the fraction of patients with each level of HER2 expression among the four cohorts ( P = 0.387, χ 2 test). B, Stacked bar chart showing that the HR−/HER2− (triple-negative) phenotype is more frequent in the cores from the NHB patients ( P = 0.004, Fisher exact test). HR, hormone receptor (ER and PR); PPN, percent positive nuclei.
Year:
2025
High expression of the proliferative marker Ki-67 is more frequent among cores from the NHB cohort. A, Boxplots comparing Ki-67% positivity as a function of the cohort. B, Risk categories for Ki-67 (low risk, 14 PPN) are shown as stacked bar charts. Supplementary Table S13 tabulates these data (see rows Ki-67 PPN and Ki-67 risk category). PPN, percent positive nuclei.
Year:
2025
Breast cancer is a leading cause of cancer-related mortality among women worldwide and is known to have higher mortality among women with African ancestry. Herein, we describe the creation and characterization of a multiethnic breast cancer tissue microarray (ME-BrTMA) representing tumors from non-Hispanic White ( n = 41), non-Hispanic Black (NHB; n = 45), and Hispanic patients from Puerto Rico ( n = 36) and Florida ( n = 52). This ME-BrTMA comprises five blocks with a total of 610 cores: 371 breast cancer tumor cores, 93 breast stromal cores, 96 normal breast tissue cores, 30 non–breast cancer tumor cores, and 20 cores representing normal tissues. Initial characterization of the ME-BrTMA includes standard IHC staining of well-characterized clinical biomarkers, including the estrogen hormone receptors and progesterone hormone receptors, HER2, and Ki-67, interpreted by the coauthoring pathologist (Marilin Rosa). The IHC results indicated good but imperfect alignment with clinical diagnoses. Cores from breast cancer tumors from the NHB cohort most frequently scored negative for estrogen receptor (63%, P P P P Significance: The ME-BrTMA described herein provides a resource that may serve as a tool to understand the underlying biology of breast cancer.
Year:
2025
PAM50 analysis shows that basal-like subtype is most frequent among NHBs. Stacked bar chart shows the results of PAM50 gene expression analysis on patients represented on the ME-BrTMA with available RNA sequencing data. The data show that the basal-like subtype is most frequent among NHBs represented on the TMA ( P = 0.031). Supplementary Table S15 tabulates the PAM50 subgroup breakdown by cohort. Note that RNA sequencing data for the NHW patients in cohort 1 are not included because they are not available.
Year:
2025
The frequency of ER-negative and PR-negative expression is highest in tumor cores from patients in the NHB cohort. A, Stacked bar chart showing that the frequency of negative ER expression is highest in cores from the NHB cohort (Fisher exact test, P = 0.001). B, Stacked bar chart showing that the frequency of PR-negative expression is highest in cores from the NHB cohort (χ 2 test, P = 0.003). C, Stacked bar chart showing that the frequency of HR-negative expression is highest in cores from the NHB cohort (χ 2 test, P = 0.006, χ 2 test). PPN, percent positive nuclei.
Year:
2025
Metadata of the brain and extracranial melanoma metastases (Visium), and Merkel Cell Carcinoma (CosMx) samples used in the spatialGE analyses. The file also contains the accession numbers and links to the data used in this work.
Year:
2025
Impact of surgery vs. biopsy sample on signature scores. A, Breast cancer specimens from tissue resection (surgery) and punch biopsy (biopsy) were compared. B, Head and neck cancer specimens from tissue resection (surgery) and punch biopsy (biopsy) were compared.
Year:
2025
Proficiency and repeatability of the CLIA laboratory in generating 12CK GES and RSI. A, Proficiency of the CLIA laboratory compared with an established research-grade molecular genomics shared resource facility. Four samples were previously processed by the MCC Molecular Genomics Core (MGC) and available for CLIA laboratory processing. GESs were derived from both experimental conditions. The experiment was performed to determine that the CLIA laboratory was proficient in generating the expression data for the HG-U133Plus platform. Left, 12CK GES scores in MGC vs. CLIA laboratory ( r = 0.991) indicating high correlation, although signature calibration was needed. Right, RSI signature scores in MGC vs. CLIA laboratory indicating compressed RSI signal from the CLIA experiments. B, Repeatability of GES from quadruplicate samples in the CLIA laboratory. Four samples were processed in quadruplicate and arrayed in the CLIA laboratory from the same operator. GES scores were derived from each experiment. Left, 12CK GES scores had a low variability in each of the four samples. Right, RSI was identical in two samples and had low level of variability in two samples.
Year:
2025
Experimental design of CLIA validation experiments. The experiments were organized into three categories: accuracy, precision, and sample content. Each of these categories assessed different sources of variability expected to impact signature scores
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (18)
Jong Park
Professor
-
Seung Joon Kim
-
Javier Torres-Roca
Senior Member
H Lee Moffitt Cancer Center and Research Institute
Idhaliz Flores
Professor
Ponce Health Sciences University
William D Cress
Senior Member
H Lee Moffitt Cancer Center and Research Institute
Anders Berglund
H Lee Moffitt Cancer Center and Research Institute
José Antonio Oliveras Torres
Assistant Professor / Puerto Rico BioBank Co-leader
Ponce Health Sciences University
Harold I Saavedra
Professor
Ponce Health Sciences University
Niki Zacharias Millward
Associate Professor
The University of Texas MD Anderson Cancer Center
Timothy Shaw
Assistant Member/Professor
Moffitt Cancer Center
Brooke Fridley
Director
Children's Mercy Hospital
Silvia Regina Rogatto
University of Southern Denmark
Inna Smalley
H Lee Moffitt Cancer Center and Research Institute
Paulo Rodriguez
Senior Member-Professor
H Lee Moffitt Cancer Center and Research Institute
Xiaoqing Yu
Associate Professor
H Lee Moffitt Cancer Center and Research Institute
Dung-Tsa Chen
H Lee Moffitt Cancer Center and Research Institute
Kenneth Tsai
Vice Chair of Research, Senior Member
H Lee Moffitt Cancer Center and Research Institute
Paul Stewart
Research Associate Professor
University of Utah
Make your next move.
Prepare your application
Review drafts before you send them.